These findings mechanistically explain how AR gets reprogrammed, away from prodifferentiation physiological functions, to instead fuel PCa growth and survival, and offer NSD1 and NSD2 as therapeutic vulnerabilities in the advanced disease. This evidence concerns the gene NSD2 and posterior cortical atrophy.